| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yu Kakimoto, Atsushi Ueda, Masatoshi Ito, Masayuki Tanaka, Tomoko Kubota, Shotaro Isozaki, Motoki Osaw. Proteomic profiling of sudden cardiac death with acquired cardiac hypertrophy. International journal of legal medicine. 2023-06-07. PMID:37284852. |
however, it is sometimes difficult to differentiate scd with acquired cardiac hypertrophy (sch) from compensated cardiac hypertrophy (cch), at autopsy. |
2023-06-07 |
2023-08-14 |
Not clear |
| Dong-Woo Lim, Hyuck Kim, Young-Mi Kim, Young-Won Chin, Won-Hwan Park, Jai-Eun Ki. Drug repurposing in alternative medicine: herbal digestive Sochehwan exerts multifaceted effects against metabolic syndrome. Scientific reports. vol 9. issue 1. 2020-11-09. PMID:31227732. |
histologic analysis of mice liver and adipose tissue showed that sch administration attenuated hepatic steatosis and hypertrophy of adipose tissue. |
2020-11-09 |
2023-08-13 |
mouse |
| Yu Kakimoto, Masayuki Tanaka, Hideki Hayashi, Keiko Yokoyama, Motoki Osaw. Overexpression of miR-221 in sudden death with cardiac hypertrophy patients. Heliyon. vol 4. issue 6. 2020-10-01. PMID:30009269. |
in this study, we investigated whether mirna expression is altered in scd with cardiac hypertrophy (sch). |
2020-10-01 |
2023-08-13 |
human |
| Fen Ai, Qing-Hao Guo, Bo Yu, Wei Li, Xin Guo, Zhen Che. Schisandrin B attenuates pressure overload-induced cardiac remodeling in mice by inhibiting the MAPK signaling pathway. Experimental and therapeutic medicine. vol 18. issue 6. 2020-10-01. PMID:31798701. |
the aim of the current study was to investigate the effect and mechanism of schisandrin b (sch b) on myocardial hypertrophy induced by pressure overload in mice. |
2020-10-01 |
2023-08-13 |
mouse |
| Yu Kakimoto, Ayumi Sasaki, Maki Niioka, Noboru Kawabe, Motoki Osaw. Myocardial cathepsin D is downregulated in sudden cardiac death. PloS one. vol 15. issue 3. 2020-06-23. PMID:32176724. |
in age-matched groups, cardiac ctsd was significantly downregulated in sch (p = 0.006) and ctsl was moderately downregulated in cch (p = 0.021); however, p62, atpsc, and asnc were not upregulated in cardiac hypertrophy. |
2020-06-23 |
2023-08-13 |
human |
| Yu Kakimoto, Ayumi Sasaki, Maki Niioka, Noboru Kawabe, Motoki Osaw. Myocardial cathepsin D is downregulated in sudden cardiac death. PloS one. vol 15. issue 3. 2020-06-23. PMID:32176724. |
subjects were classified into three groups: scd with cardiac hypertrophy (sch), compensated cardiac hypertrophy (cch), and control. |
2020-06-23 |
2023-08-13 |
human |
| Marcus Dörr, Till Ittermann, Nicole Aumann, Anne Obst, Thorsten Reffelmann, Matthias Nauck, Henri Wallaschofski, Stephan B Felix, Henry Völzk. Subclinical hyperthyroidism is not associated with progression of cardiac mass and development of left ventricular hypertrophy in middle-aged and older subjects: results from a 5-year follow-up. Clinical endocrinology. vol 73. issue 6. 2011-03-04. PMID:20874773. |
decreased serum tsh levels are associated with increased cardiovascular mortality in elderly, and subclinical hyperthyroidism (sch) was associated with left ventricular hypertrophy (lvh) as a predictor of cardiovascular mortality in some cross-sectional and case-control studies. |
2011-03-04 |
2023-08-12 |
human |
| Tami A Martino, Gavin Y Oudit, Andrew M Herzenberg, Nazneen Tata, Margaret M Koletar, Golam M Kabir, Denise D Belsham, Peter H Backx, Martin R Ralph, Michael J Sol. Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. American journal of physiology. Regulatory, integrative and comparative physiology. vol 294. issue 5. 2008-06-18. PMID:18272659. |
moreover, hypertrophy does not develop in animals whose suprachiasmatic nucleus was ablated as young adults. |
2008-06-18 |
2023-08-12 |
Not clear |
| Paul E Goss, Shangle Qi, Angela M Cheung, Haiqing Hu, Maria Mendes, Kenneth P H Pritzke. The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. The Journal of steroid biochemistry and molecular biology. vol 92. issue 1-2. 2005-02-10. PMID:15544933. |
the selective estrogen receptor modulator sch 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats. |
2005-02-10 |
2023-08-12 |
rat |
| L E Stuh. Effects of SCH 42495, a neutral endopeptidase inhibitor, on cardiac function and mass in rats after repeated hyperbaric exposures. Scandinavian journal of clinical and laboratory investigation. vol 60. issue 2. 2000-08-02. PMID:10817401. |
the aim of the present study was to investigate the effects of inhibition of neutral endopeptidase on left ventricular hypertrophy (lvh), myocardial necrosis and haemodynamic changes, previously shown in rats after repeated hyperbaric exposures to 5 bar, by using the novel neutral endopeptidase inhibitor sch 42495. |
2000-08-02 |
2023-08-12 |
rat |
| P K Ganguly, K Mukherjee, A Saha. Renal dopamine receptors are involved in the development of cardiac hypertrophy. Molecular and cellular biochemistry. vol 144. issue 1. 1995-07-25. PMID:7791750. |
treatment with sch 23390, a da1 antagonist, on the other hand, was able to partially regress the cardiac hypertrophic changes. |
1995-07-25 |
2023-08-12 |
rat |
| J S Thompson, W Sheedy, A H Moric. Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia. British journal of pharmacology. vol 113. issue 4. 1995-04-19. PMID:7889263. |
treatment with sch 42495 caused a significant reduction in pulmonary vascular remodelling (25.0 +/- 0.01%) and right ventricular hypertrophy (0.52 +/- 0.09) in cht20 rats compared with chv20 controls (33.0 +/- 0.02% and 0.61 +/- 0.09 respectively). |
1995-04-19 |
2023-08-12 |
rat |
| K Mukherjee, A Sahai, P K Gangul. Renal D1 receptors, and not D2, are upregulated after aortic constriction and may be involved in cardiac hypertrophy. Journal of autonomic pharmacology. vol 14. issue 4. 1995-01-05. PMID:7983081. |
reversal of hypertrophic parameters was observed in the aortic banded group treated for 14 days with sch 23390 hydrochloride (0.1 mg kg-1 i.p. |
1995-01-05 |
2023-08-12 |
rat |
| J S Thompson, W Sheedy, A H Moric. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats. Clinical science (London, England : 1979). vol 87. issue 1. 1994-09-22. PMID:8062513. |
treatment with sch 42495 caused a significant reduction in the pulmonary vascular remodelling and ventricular hypertrophy in hypoxic rats after 10 days. |
1994-09-22 |
2023-08-12 |
rat |
| I Antony, D Chemla, Y Lecarpentie. Myocardial contractility, lusitropy and calcium responsiveness in young (50 days) and hypertrophied (180 days) cardiomyopathic hamsters. Journal of molecular and cellular cardiology. vol 24. issue 10. 1993-02-11. PMID:1479611. |
contractility, lusitropy and responsiveness to the increase of external ca2+ concentration were studied in left ventricular papillary muscles of normal and cardiomyopathic syrian hamsters (sch) from the um-x 7.1 strain, both at the onset of myolysis (50-day-old animals) and at the cardiac hypertrophy stage (180-day-old animals) in the absence of congestive heart failure. |
1993-02-11 |
2023-08-11 |
Not clear |
| A M Richards, I G Crozier, E A Espiner, H Ikram, T G Yandle, T Kosoglou, M Rallings, C Frampto. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. Journal of cardiovascular pharmacology. vol 20. issue 5. 1992-12-31. PMID:1280735. |
the acute renal, endocrine, and hemodynamic effects of the orally active endopeptidase inhibitor sch 34826 (400 mg every 6 hours for five doses) were investigated in a group of 6 male patients [with established mild to moderate essential hypertension and left ventricular (lv) hypertrophy] in a balanced random-order double-blind, placebo-controlled cross-over study. |
1992-12-31 |
2023-08-11 |
Not clear |
| A Monopoli, E Ongini, E Cigola, G Olivett. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Journal of cardiovascular pharmacology. vol 20. issue 3. 1992-12-09. PMID:1279298. |
the effects of sch 34826 on hypertension and left ventricular hypertrophy (lvh) in spontaneously hypertensive rats (shrs) were evaluated following 1 month of treatment by measuring the blood pressure, cardiac weight, and left ventricular fibrosis. |
1992-12-09 |
2023-08-11 |
rat |
| A Monopoli, E Ongini, E Cigola, G Olivett. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Journal of cardiovascular pharmacology. vol 20. issue 3. 1992-12-09. PMID:1279298. |
the neutral endopeptidase inhibitor, sch 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. |
1992-12-09 |
2023-08-11 |
rat |
| A Monopoli, E Ongini, E Cigola, G Olivett. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. Journal of cardiovascular pharmacology. vol 20. issue 3. 1992-12-09. PMID:1279298. |
these data indicate that chronic inhibition of nep by sch 34826 interacts with mechanisms underlying myocardial hypertrophy and cardiac remodeling. |
1992-12-09 |
2023-08-11 |
rat |
| A G Stewart, W Sheedy, J S Thompson, A H Moric. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling. Pulmonary pharmacology. vol 5. issue 2. 1992-07-24. PMID:1535251. |
administration of sch 34826 caused a significant reduction in the hypoxia-induced pulmonary vascular remodelling and right ventricle hypertrophy. |
1992-07-24 |
2023-08-11 |
rat |